Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Parallel, Observer-blind Study to Assess the Safety and Immunogenicity of an Egg-based H5N8 Influenza Vaccine at Multiple Dose Levels Adjuvanted With Matrix-M in Healthy Participants 18 Years of Age and Above.

NCT07779408 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT07779408
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07779408 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Parallel, Observer-blind Study to Assess the Safety and Immunogenicity of an Egg-based H5N8 Influenza Vaccine at Multiple Dose Levels Adjuvanted With Matrix-M in Healthy Participants 18 Years of Age and Above.
Lead sponsor
Sanofi
Phase
Phase 1/2
Overall status
Recruiting
Start date
August 3, 2026
Completion date
February 22, 2028
Enrollment
640 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers, influenza